Quantum-Si Incorporated announced its financial results for the first quarter ended March 31, 2025, reporting revenue of $842,000. The gross profit for the quarter was $486,000, with a gross margin of 58%.
Total operating expenses for Q1 2025 were $25.6 million, and adjusted operating expenses were $22.9 million. The net loss for the quarter was $19.2 million, and adjusted EBITDA was negative $21.5 million.
As of March 31, 2025, the company held $232.6 million in cash, cash equivalents, and marketable securities, following a $50 million registered direct offering completed on January 6, 2025. This capital provides a cash runway into the second half of 2027.
Quantum-Si launched Platinum Pro and completed training for its North American channel partner, Avantor, while expanding its international channel partner network to 23 partners. However, the company noted challenges in the U.S. life sciences market due to NIH funding and tariff uncertainty.
Despite U.S. headwinds, Quantum-Si remains optimistic about opportunities in biopharma and international markets. The company's R&D team is on track for a Q3 2025 launch of its Version 4 Sequencing Kit, a Q4 2025 launch of a Version 3 Library Preparation Kit, and successful protein sequencing on a Proteus prototype by the end of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.